JP2003534246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003534246A5 JP2003534246A5 JP2001572454A JP2001572454A JP2003534246A5 JP 2003534246 A5 JP2003534246 A5 JP 2003534246A5 JP 2001572454 A JP2001572454 A JP 2001572454A JP 2001572454 A JP2001572454 A JP 2001572454A JP 2003534246 A5 JP2003534246 A5 JP 2003534246A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- condition
- treating
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 20
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000002246 antineoplastic agent Substances 0.000 description 13
- 229940127089 cytotoxic agent Drugs 0.000 description 13
- 230000003211 malignant effect Effects 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108091008726 retinoic acid receptors α Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 108091008761 retinoic acid receptors β Proteins 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54214800A | 2000-04-04 | 2000-04-04 | |
| US09/542,148 | 2000-04-04 | ||
| PCT/US2001/010410 WO2001074759A1 (en) | 2000-04-04 | 2001-04-02 | Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003534246A JP2003534246A (ja) | 2003-11-18 |
| JP2003534246A5 true JP2003534246A5 (https=) | 2008-05-15 |
Family
ID=24162539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572454A Pending JP2003534246A (ja) | 2000-04-04 | 2001-04-02 | ＲＡＲα選択的レチノイド化合物と他の抗腫瘍剤との併用による腫瘍の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6387950B2 (https=) |
| EP (2) | EP1650188A1 (https=) |
| JP (1) | JP2003534246A (https=) |
| AT (1) | ATE331703T1 (https=) |
| AU (1) | AU2001253045A1 (https=) |
| CA (1) | CA2405136C (https=) |
| DE (1) | DE60121145T2 (https=) |
| ES (1) | ES2267754T3 (https=) |
| TW (1) | TWI281911B (https=) |
| WO (1) | WO2001074759A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903121B1 (en) | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| SI1324970T1 (sl) * | 2000-10-02 | 2009-02-28 | Hoffmann La Roche | Retinoidi za zdravljenje emfizema |
| EP1935869A1 (en) * | 2000-10-02 | 2008-06-25 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| WO2005093426A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) |
| CN101316583A (zh) | 2005-09-30 | 2008-12-03 | 生命医药公司 | 用特异性rxr激动剂治疗癌症 |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| WO2013090616A1 (en) | 2011-12-13 | 2013-06-20 | Io Therapeutics, Inc. | Autoimmune disorder treatment using rxr agonists |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| PL3277272T3 (pl) | 2015-03-31 | 2022-01-24 | Syros Pharmaceuticals, Inc. | Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego |
| CN116077626A (zh) | 2015-10-31 | 2023-05-09 | Io治疗公司 | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 |
| EP3380086B1 (en) | 2015-11-25 | 2021-10-13 | IO Therapeutics, Inc. | Cyp26-resistant rar-alpha selective agonists in the treatment of cancer |
| US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
| KR102605349B1 (ko) | 2016-03-10 | 2023-11-22 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| WO2017177167A1 (en) | 2016-04-08 | 2017-10-12 | Syros Pharmaceuticals, Inc. | Rara agonists for the treatment of aml and mds |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) * | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CA3242047A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| AU2022408160A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist and taxanes in treating her2+ cancers |
| CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
| JP2025521810A (ja) | 2022-06-27 | 2025-07-10 | アイオー セラピューティクス インコーポレイテッド | テトラヒドロナフタレノール類の合成およびその用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4001618B2 (ja) * | 1991-12-18 | 2007-10-31 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物 |
| US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
2001
- 2001-03-30 TW TW090107695A patent/TWI281911B/zh not_active IP Right Cessation
- 2001-04-02 EP EP05025970A patent/EP1650188A1/en not_active Withdrawn
- 2001-04-02 ES ES01926512T patent/ES2267754T3/es not_active Expired - Lifetime
- 2001-04-02 EP EP01926512A patent/EP1268405B1/en not_active Expired - Lifetime
- 2001-04-02 JP JP2001572454A patent/JP2003534246A/ja active Pending
- 2001-04-02 DE DE60121145T patent/DE60121145T2/de not_active Expired - Lifetime
- 2001-04-02 AT AT01926512T patent/ATE331703T1/de not_active IP Right Cessation
- 2001-04-02 AU AU2001253045A patent/AU2001253045A1/en not_active Abandoned
- 2001-04-02 US US09/824,111 patent/US6387950B2/en not_active Expired - Fee Related
- 2001-04-02 WO PCT/US2001/010410 patent/WO2001074759A1/en not_active Ceased
- 2001-04-02 CA CA002405136A patent/CA2405136C/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534246A5 (https=) | ||
| US7226910B2 (en) | Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists | |
| JP6377664B2 (ja) | 薬学的組成物 | |
| JP2002532392A5 (https=) | ||
| RU2004129577A (ru) | Лекарственные композиции с замедленным высвобождением, содержащие пептид-носитель | |
| JP2005515966A5 (https=) | ||
| JP2004504406A5 (https=) | ||
| CA2440111A1 (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
| ATE526950T1 (de) | Hydrocodon-formulierungen mit gesteuerter freisetzung | |
| JP2005520778A5 (https=) | ||
| NZ527113A (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| JP2002514598A5 (https=) | ||
| JP2003519228A5 (https=) | ||
| JP2003509371A (ja) | ５−ヒドロキシトリプタミン・レセプタ／α２アドレナリン作用性レセプタ拮抗薬組成物の投与による運動障害の処置 | |
| JP2002520282A5 (https=) | ||
| FR2798065B1 (fr) | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| JP2024510260A5 (https=) | ||
| JPH10147529A5 (https=) | ||
| JP2002504505A5 (https=) | ||
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| JP2002544227A5 (https=) | ||
| JP6743001B2 (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| JP2003514025A5 (https=) | ||
| JP4453254B2 (ja) | レストレス・レッグズ症候群治療薬 |